Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon
This letter describes the experience of the American University of Beirut Medical Center in Lebanon with haploidentical stem cell transplant (haplo-SCT) for hematological malignancies in adult patients. Haplo-SCT made it possible through universal and rapid donor availability for most of the adult p...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Transplantation |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frtra.2023.1149393/full |
| _version_ | 1797806304493830144 |
|---|---|
| author | Jean El Cheikh Jean El Cheikh Ghassan Bidaoui Layal Sharrouf Ammar Zahreddine Radwan Massoud Radwan Massoud Rita Nehme Nabila Kreidieh Nour Moukalled Nour Moukalled Iman Abou Dalle Iman Abou Dalle Rami Mahfouz Ali Bazarbachi Ali Bazarbachi |
| author_facet | Jean El Cheikh Jean El Cheikh Ghassan Bidaoui Layal Sharrouf Ammar Zahreddine Radwan Massoud Radwan Massoud Rita Nehme Nabila Kreidieh Nour Moukalled Nour Moukalled Iman Abou Dalle Iman Abou Dalle Rami Mahfouz Ali Bazarbachi Ali Bazarbachi |
| author_sort | Jean El Cheikh |
| collection | DOAJ |
| description | This letter describes the experience of the American University of Beirut Medical Center in Lebanon with haploidentical stem cell transplant (haplo-SCT) for hematological malignancies in adult patients. Haplo-SCT made it possible through universal and rapid donor availability for most of the adult patients with leukemia or lymphoma not only in the Middle East but also globally. Moreover, the use of post-transplant cyclophosphamide (PTCy) and reduced intensity conditioning (RIC) regimens when indicated improved the outcome and decreased the toxicity of haploidentical stem cell transplant.RIC regimens also allowed its use in the elderly population. Patients from throughout the Middle East come to our center, the American university of Beirut Medical Center, to receive this transformative type of stem cell transplant. In this paper, we discuss the results of haplo-SCT with PTCy done on adult patients with hematological malignancies in our center from 2015 to 2021. The results are encouraging and show that haplo-SCT should be considered more often in the Middle Eastern countries. The subgroup analysis showed the importance of achieving complete remission of the disease prior to transplant to improve outcomes in our center. There is a paucity of literature on the outcomes of haplo-SCT in the Middle East which may contribute to the limited number of centers that offer this type of SCT. Herein, we aim to fill this gap in the hopes of encouraging the implementation of this potentially curative modality of treatment to a larger extent in the Middle East. |
| first_indexed | 2024-03-13T06:05:19Z |
| format | Article |
| id | doaj.art-6e9f67ef99f646919145f420bc65d686 |
| institution | Directory Open Access Journal |
| issn | 2813-2440 |
| language | English |
| last_indexed | 2024-03-13T06:05:19Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Transplantation |
| spelling | doaj.art-6e9f67ef99f646919145f420bc65d6862023-06-12T04:25:45ZengFrontiers Media S.A.Frontiers in Transplantation2813-24402023-06-01210.3389/frtra.2023.11493931149393Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in LebanonJean El Cheikh0Jean El Cheikh1Ghassan Bidaoui2Layal Sharrouf3Ammar Zahreddine4Radwan Massoud5Radwan Massoud6Rita Nehme7Nabila Kreidieh8Nour Moukalled9Nour Moukalled10Iman Abou Dalle11Iman Abou Dalle12Rami Mahfouz13Ali Bazarbachi14Ali Bazarbachi15Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonDivision of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonDivision of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonDivision of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonDepartment of Pathology and Laboratory Medicine, American University of Beirut, Beirut, LebanonDivision of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonDivision of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonDepartment of Pathology and Laboratory Medicine, American University of Beirut, Beirut, LebanonDivision of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, LebanonThis letter describes the experience of the American University of Beirut Medical Center in Lebanon with haploidentical stem cell transplant (haplo-SCT) for hematological malignancies in adult patients. Haplo-SCT made it possible through universal and rapid donor availability for most of the adult patients with leukemia or lymphoma not only in the Middle East but also globally. Moreover, the use of post-transplant cyclophosphamide (PTCy) and reduced intensity conditioning (RIC) regimens when indicated improved the outcome and decreased the toxicity of haploidentical stem cell transplant.RIC regimens also allowed its use in the elderly population. Patients from throughout the Middle East come to our center, the American university of Beirut Medical Center, to receive this transformative type of stem cell transplant. In this paper, we discuss the results of haplo-SCT with PTCy done on adult patients with hematological malignancies in our center from 2015 to 2021. The results are encouraging and show that haplo-SCT should be considered more often in the Middle Eastern countries. The subgroup analysis showed the importance of achieving complete remission of the disease prior to transplant to improve outcomes in our center. There is a paucity of literature on the outcomes of haplo-SCT in the Middle East which may contribute to the limited number of centers that offer this type of SCT. Herein, we aim to fill this gap in the hopes of encouraging the implementation of this potentially curative modality of treatment to a larger extent in the Middle East.https://www.frontiersin.org/articles/10.3389/frtra.2023.1149393/fullhaploidentical hematopoietic stem cell transplantationlow- and lower-middle-income countrieshematologic malignanciespost transplant cyclophosphamidetertiaiy care |
| spellingShingle | Jean El Cheikh Jean El Cheikh Ghassan Bidaoui Layal Sharrouf Ammar Zahreddine Radwan Massoud Radwan Massoud Rita Nehme Nabila Kreidieh Nour Moukalled Nour Moukalled Iman Abou Dalle Iman Abou Dalle Rami Mahfouz Ali Bazarbachi Ali Bazarbachi Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon Frontiers in Transplantation haploidentical hematopoietic stem cell transplantation low- and lower-middle-income countries hematologic malignancies post transplant cyclophosphamide tertiaiy care |
| title | Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon |
| title_full | Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon |
| title_fullStr | Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon |
| title_full_unstemmed | Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon |
| title_short | Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon |
| title_sort | haploidentical stem cell transplantation with post transplant cyclophosphamide challenges and outcome from a tertiary care center in lebanon |
| topic | haploidentical hematopoietic stem cell transplantation low- and lower-middle-income countries hematologic malignancies post transplant cyclophosphamide tertiaiy care |
| url | https://www.frontiersin.org/articles/10.3389/frtra.2023.1149393/full |
| work_keys_str_mv | AT jeanelcheikh haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT jeanelcheikh haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT ghassanbidaoui haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT layalsharrouf haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT ammarzahreddine haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT radwanmassoud haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT radwanmassoud haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT ritanehme haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT nabilakreidieh haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT nourmoukalled haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT nourmoukalled haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT imanaboudalle haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT imanaboudalle haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT ramimahfouz haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT alibazarbachi haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon AT alibazarbachi haploidenticalstemcelltransplantationwithposttransplantcyclophosphamidechallengesandoutcomefromatertiarycarecenterinlebanon |